One emerging therapeutic strategy involves inhibition of NADPH oxidase (NOX) enzymatic activity, with compounds such as ebselen, S17834, and GKT137831 showing potential across various disease models
Most importantly, this protective phenotype appears to involve the following beneficial cellular adaptions: (i) enhanced metabolism of ethanol and acetaldehyde, (ii) suppression of lipogenic genes and induction of genes involved in fatty acid oxidation, and (iii) induction of the NRF2 antioxidant response and the AMPK metabolic signaling pathway
Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor
Other sites include ankle, knee, thigh, hand, gastrointestinal tract and penis
[DOI] [PMC free article] [PubMed] [Google Scholar] 27.Ranque B., Kitenge R., Ndiaye D.D., Ba M.D., Adjoumani L., Traore H., Coulibaly C., Guindo A., Boidy K., Mbuyi D., et al
Save this and look it up tonight